Evidence map›Paper›PMID 31412000›Full record

ArticleEuropean urology oncology2020

Multiregion Quantification of Extracellular Signal-regulated Kinase Activity in Renal Cell Carcinoma.

Christian R Hoerner, Rustin Massoudi, Thomas J Metzner, Laurel Stell, Jennifer J O'Rourke, Christina S Kong, Joanna E Liliental, James D Brooks, Chiara Sabatti, John T Leppert and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European urology oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Christian R HoernerDivision of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA; The Kidney Cancer Research Program, Stanford University School of Medicine, Stanford, CA, USA.
Rustin MassoudiThe Kidney Cancer Research Program, Stanford University School of Medicine, Stanford, CA, USA; Department of Urology, Stanford University School of Medicine, Stanford, CA, USA.
Thomas J MetznerThe Kidney Cancer Research Program, Stanford University School of Medicine, Stanford, CA, USA; Department of Urology, Stanford University School of Medicine, Stanford, CA, USA; Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA.
Laurel StellDepartment of Biomedical Data Science, Stanford University School of Medicine, Stanford, CA, USA.
Jennifer J O'RourkeDivision of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA; The Kidney Cancer Research Program, Stanford University School of Medicine, Stanford, CA, USA.
Christina S KongDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Joanna E LilientalStanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA; Translational Applications Service Center (TASC) and Translational Research and Applied Medicine (TRAM) Program, Stanford University School of Medicine, Stanford, CA, USA.
James D BrooksThe Kidney Cancer Research Program, Stanford University School of Medicine, Stanford, CA, USA; Department of Urology, Stanford University School of Medicine, Stanford, CA, USA; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA; Bio-X, Stanford University, Stanford, CA, USA.
Chiara SabattiDepartment of Biomedical Data Science, Stanford University School of Medicine, Stanford, CA, USA; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA; Bio-X, Stanford University, Stanford, CA, USA; Department of Statistics, Stanford University, Stanford, CA, USA.
John T LeppertThe Kidney Cancer Research Program, Stanford University School of Medicine, Stanford, CA, USA; Department of Urology, Stanford University School of Medicine, Stanford, CA, USA; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA; Bio-X, Stanford University, Stanford, CA, USA; Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA; Division of Nephrology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA. Electronic address: jleppert@stanford.edu.
Alice C FanDivision of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA; The Kidney Cancer Research Program, Stanford University School of Medicine, Stanford, CA, USA; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA; Bio-X, Stanford University, Stanford, CA, USA. Electronic address: afan@stanford.edu.
Stanford University · USVA Palo Alto Health Care System · US

Funding

Spectrum Stanford Center for clinical and Translational Research and EducationUL1TR001085 · NCATS · STANFORD UNIVERSITY · PI CULLEN, MARK RICHARD, GREENBERG, HARRY BERNARD · 2013 to 2017
$37.1M
Analysis of CTCs for Early Prediction of Response to Treatment in RCCR21CA185804 · NCI · STANFORD UNIVERSITY · PI FAN, ALICE CHEN, WANG, SHAN X. · 2015 to 2016
$383k
Nanoscale proteomic profiles of hypoxia pathways to develop biomarkers of renal cR21CA169964 · NCI · STANFORD UNIVERSITY · PI FELSHER, DEAN W, LEPPERT, JOHN THOMAS · 2012 to 2013
$330k
NCATS NIH HHS UL1 TR001085NCI NIH HHS R21 CA169964NCI NIH HHS R21 CA185804
6 · The paper itself

Abstract

To personalize treatment for renal cell carcinoma (RCC), it would be ideal to confirm the activity of druggable protein pathways within individual tumors. We have developed a high-resolution nanoimmunoassay (NIA) to measure protein activity with high precision in scant specimens (eg, fine needle aspirates [FNAs]). Here, we used NIA to determine whether protein activation varied in different regions of RCC tumors. Since most RCC therapies target angiogenesis by inhibiting the vascular endothelial growth factor (VEGF) receptor, we quantified phosphorylation of extracellular signal-regulated kinase (ERK), a downstream effector of the VEGF signaling pathway. In 90 ex vivo FNA biopsies sampled from multiple regions of 38 primary clear cell RCC tumors, ERK phosphorylation differed among patients. In contrast, within individual patients, we found limited intratumoral heterogeneity of ERK phosphorylation. Our results suggest that measuring ERK in a single FNA may be representative of ERK activity in different regions of the same tumor. As diagnostic and therapeutic protein biomarkers are being sought, NIA measurements of protein signaling may increase the clinical utility of renal mass biopsy and allow for the application of precision oncology for patients with localized and advanced RCC. PATIENT SUMMARY: In this report, we applied a new approach to measure the activity of extracellular signal-regulated kinase (ERK), a key cancer signaling protein, in different areas within kidney cancers. We found that ERK activity varied between patients, but that different regions within individual kidney tumors showed similar ERK activity. This suggests that a single biopsy of renal cell carcinoma may be sufficient to measure protein signaling activity to aid in precision oncology approaches.

Indexed as

Carcinoma, Renal CellExtracellular Signal-Regulated MAP KinasesHumansKidney NeoplasmsExtracellular Signal-Regulated MAP KinasesExtracellular signal-regulated kinaseFine needle aspirateIntertumor heterogeneityIntratumor heterogeneityKidney cancerPhosphorylationProtein signalingRenal cell carcinoma

Identifiers

PMID31412000
PMCPMC6697234
OpenAlexW2901911687

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.